OABI vs. NRC, MXCT, ABSI, CORS, DTRT, LUNA, DSAQ, GWII, WRAC, and NOTV
Should you be buying OmniAb stock or one of its competitors? The main competitors of OmniAb include National Research (NRC), MaxCyte (MXCT), Absci (ABSI), Corsair Partnering (CORS), DTRT Health Acquisition (DTRT), Luna Innovations (LUNA), Direct Selling Acquisition (DSAQ), Good Works II Acquisition (GWII), Williams Rowland Acquisition (WRAC), and Inotiv (NOTV).
National Research (NASDAQ:NRC) and OmniAb (NASDAQ:OABI) are both small-cap business services companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, dividends, media sentiment, institutional ownership, valuation, community ranking and profitability.
OmniAb has a consensus price target of $9.00, indicating a potential upside of 93.97%. Given National Research's higher possible upside, analysts clearly believe OmniAb is more favorable than National Research.
National Research has a beta of 0.56, suggesting that its share price is 44% less volatile than the S&P 500. Comparatively, OmniAb has a beta of -0.08, suggesting that its share price is 108% less volatile than the S&P 500.
47.3% of National Research shares are owned by institutional investors. Comparatively, 72.1% of OmniAb shares are owned by institutional investors. 2.0% of National Research shares are owned by company insiders. Comparatively, 8.6% of OmniAb shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
In the previous week, National Research had 1 more articles in the media than OmniAb. MarketBeat recorded 2 mentions for National Research and 1 mentions for OmniAb. OmniAb's average media sentiment score of -0.84 beat National Research's score of -0.99 indicating that National Research is being referred to more favorably in the media.
National Research has a net margin of 20.60% compared to National Research's net margin of -301.62%. OmniAb's return on equity of 54.83% beat National Research's return on equity.
National Research received 93 more outperform votes than OmniAb when rated by MarketBeat users. However, 100.00% of users gave OmniAb an outperform vote while only 61.67% of users gave National Research an outperform vote.
National Research has higher revenue and earnings than OmniAb. OmniAb is trading at a lower price-to-earnings ratio than National Research, indicating that it is currently the more affordable of the two stocks.
Summary
National Research beats OmniAb on 11 of the 17 factors compared between the two stocks.
Get OmniAb News Delivered to You Automatically
Sign up to receive the latest news and ratings for OABI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OABI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
